Aripiprazole CAS 129722-12-9 Raw Materials Powder

CAS: 129722-12-9

MF: C23H27Cl2N3O2

Specification​: 99% min Aripiprazole Powder

Sample:  Aripiprazole Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Aripiprazole Powder Usage and Synthesis:

Aripiprazole (Alprazolam) is a benzodiazepine commonly used to treat psychiatric disorders such as anxiety, panic disorder, and depression. It reduces anxiety and panic symptoms by enhancing the action of the neurotransmitter gamma-aminobutyric acid (GABA). Aripiprazole is a prescription drug and requires a doctor's prescription to purchase.
Because of its addictive properties and risk of abuse, its use should follow your doctor's advice and should not be increased or decreased in dose or used for long periods of time. Also, Aripiprazole has some side effects such as drowsiness, dizziness and muscle weakness, so you need to be careful when using it safely.

Applications of Aripiprazole Powder :

Aripiprazole Powder is commonly used as a raw material for the treatment of anxiety, panic disorder, depression and other psychiatric disorders.Aripiprazole Raw Materials is used to reduce anxiety and panic symptoms.Aripiprazole CAS 129722-12-9 is a new highly fat-soluble quinolone derivative with pharmacological characteristics, namely Aripiprazole is a novel, highly lipid-soluble quinolone derivative with pharmacological properties as a postsynaptic dopamine D 2 receptor antagonist and a presynaptic dopamine D 2 receptor agonist.

Pharmacological Effect of Aripiprazole Powder:

Aripiprazole is a new highly lipid-soluble quinolone derivative, whose pharmacological action is characterized as a postsynaptic dopamine D2 receptor antagonist and a presynaptic dopamine D2 receptor agonist. It also has agonistic effects on D1, D3 and D4 receptors; it has a dual effect of partial receptor antagonism or activation on 5-HT1A receptors; and a complete antagonistic effect on 5-HT2A receptors.

This feature is different from the first generation and atypical antipsychotic drugs, i.e., the second generation antipsychotic drugs, and is therefore called dopamine system stabilizers or third generation antipsychotic drugs.

Since the last century, it is mainly used clinically for the treatment of schizophrenia, schizoaffective psychosis and other psychotic disorders. According to the literature, aripiprazole has been reported to have significant efficacy on both positive and negative symptoms of schizophrenia and on anxiety, depression, and cognitive function, while having a higher safety profile.

It has also been reported to treat other psychiatric disorders such as manic episodes of affective disorders, senile dementia with psychotic disorders, anxiety disorders, childhood behavior disorders, depression, etc.

The metabolic pathway of aripiprazole is mainly through 3 biotransformations: dehydrogenation, hydroxylation and N-dealkylation. In vitro studies have shown that CYP3A4 and CYP2D6 are the two enzymes involved in the metabolism of this product. CYP3A4 and CYP2D6 are responsible for dehydrogenation and hydroxylation, while N-dealkylation is caused by CYP3A4 catalysis.

Therefore, the dosage of aripiprazole should be adjusted when drugs affecting the activity and quantity of these two enzymes are present. At steady state, the pharmacokinetics of this product are proportional to the dose. Oral administration of a single dose of 14C-labeled this product showed that 55% of the metabolites were excreted by feces, 25% by urine, 18% by feces as prodrug, and 1% by urine as prodrug.

Aripiprazole is a new highly lipid-soluble quinolone derivative, whose pharmacological action is characterized as a postsynaptic dopamine D2 receptor antagonist and a presynaptic dopamine D2 receptor agonist. It also has agonistic effects on D1, D3 and D4 receptors; it has a dual effect of partial receptor antagonism or activation on 5-HT1A receptors; and a complete antagonistic effect on 5-HT2A receptors.

This feature is different from the first generation and atypical antipsychotic drugs, i.e., the second generation antipsychotic drugs, and is therefore called dopamine system stabilizers or third generation antipsychotic drugs.

Since the last century, it is mainly used clinically for the treatment of schizophrenia, schizoaffective psychosis and other psychotic disorders. According to the literature, aripiprazole has been reported to have significant efficacy on both positive and negative symptoms of schizophrenia and on anxiety, depression, and cognitive function, while having a higher safety profile.

It has also been reported to treat other psychiatric disorders such as manic episodes of affective disorders, senile dementia with psychotic disorders, anxiety disorders, childhood behavior disorders, depression, etc.